Us Bancorp \De\ Moon Lake Immunotherapeutics Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Us Bancorp \De\ holds 869 shares of MLTX stock, worth $45,335. This represents 0.0% of its overall portfolio holdings.

Number of Shares

869

Holding current value

$45,335

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2024 Oct 28, 2024	BUY	$40.15 - $55.4 $34,890 - $48,142	869 New	869 $43,000
Q3 2023 Nov 03, 2023	BUY	$48.35 - $61.26 $171,497 - $217,289	3,547 New	3,547 $202,000

Others Institutions Holding MLTX

# of Institutions

124

Shares Held

58.2M

Call Options Held

52.2K

Put Options Held

38K

Bvf Inc San Francisco, CA

21.8M
Shares

$1.13 Billion
34.86% of portfolio
Cormorant Asset Management, LP Boston, MA

8.49M
Shares

$443 Million
30.01% of portfolio
Price T Rowe Associates Inc Baltimore, MD

2.98M
Shares

$155 Million
0.02% of portfolio
Avoro Capital Advisors LLC New York, NY

2.77M
Shares

$145 Million
2.1% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

2.32M
Shares

$121 Million
0.02% of portfolio

View Full List

About MoonLake Immunotherapeutics

Ticker MLTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,925,600
Market Cap $1.93B
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...

More about MLTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account